Aptevo Therapeutics Inc
APVO4.720USD
+0.020+0.43%
Close 05/30, 16:00（ET）Quotes delayed by 15 min
6.88MMarket Cap
LossP/E TTM
More Details of Aptevo Therapeutics Inc Company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Company Info
Company codeAPVO
Company nameAptevo Therapeutics Inc
IPO dateJul 20, 2016
Founded at2016
CEOMr. Marvin L. White
Number of employees37
Security typeOrdinary Share
Fiscal year-endJul 20
Address2401 4th Ave Ste 1050
CitySEATTLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code98121-3460
Phone12068380500
Websitehttps://aptevotherapeutics.com/
Company codeAPVO
IPO dateJul 20, 2016
Founded at2016
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
7.00
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
5.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+50.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
2.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
7.00
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
5.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+50.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
2.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Wed, May 28
Update time: Wed, May 28
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
3.11%
Bigger Capital Funds, LP
1.48%
Heights Capital Management, Inc.
1.48%
Geode Capital Management, L.L.C.
0.08%
Schiketanz Capital Advisors GmbH
0.04%
Other
93.81%
Shareholder Statistics
Shareholder
Proportion
L1 Capital Global Opportunities Master Fund Ltd.
3.11%
Bigger Capital Funds, LP
1.48%
Heights Capital Management, Inc.
1.48%
Geode Capital Management, L.L.C.
0.08%
Schiketanz Capital Advisors GmbH
0.04%
Other
93.81%
Type
Shareholder
Proportion
Corporation
3.11%
Investment Advisor
1.52%
Hedge Fund
1.50%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.04%
Other
93.75%
Institutional Shareholding
Update time: Mon, Feb 24
Update time: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
49
55.12K
0.94%
-14.63K
2024Q4
49
48.74K
3.37%
-20.87K
2024Q3
46
34.83K
7.56%
-18.81K
2024Q2
48
53.21K
48.29%
+52.02K
2024Q1
49
188.00
1.03%
-1.27K
2023Q4
51
1.27K
10.69%
-1.06K
2023Q3
56
2.18K
24.99%
+1.07K
2023Q2
60
629.00
13.58%
-1.76K
2023Q1
67
602.00
13.71%
-1.90K
2022Q4
74
629.00
16.12%
-1.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tower Research Capital LLC
1.09K
0.03%
+408.00
+60.18%
Dec 31, 2024
SBI Securities Co., Ltd.
131.00
0%
+131.00
--
Dec 31, 2024
The Vanguard Group, Inc.
56.00
0%
--
--
Jan 31, 2025
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Date
Type
Ratio
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 26, 2020
Merger
14<1
Mar 26, 2020
Merger
14<1
View more
